We were delighted to speak with our Editor-in-Chief, Professor Peter C Taylor (University of Oxford, Oxford, UK) around the safety of statin and filgotinib coadministration in patients with rheumatoid arthritis across the DARWIN and FINCH clinical trials.
The abstract ‘CONCOMITANT USE OF STATINS IN FILGOTINIB-TREATED PATIENTS WITH RHEUMATOID ARTHRITIS‘ (POS0660), was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What is the role of statins in the management of rheumatoid arthritis, and how prevalent is their use? (0:11)
- What are the potential risks of coadministration of JAK inhibitors such as filgotinib and statins? (1:04)
- Could you tell us a little about the design and inclusion criteria of your study assessing coadministration of filgotinib and statins? (1:48)
- What were the findings of this study, and what are their implications for clinical practice? (3:22)
- What other evidence supports these findings? (5:17)
Disclosures: Peter C Taylor reports receiving: Research grants from Celgene, Galapagos, Gilead and Lilly; and consultation fees from AbbVie, BMS, Biogen, Fresenius, Galapagos, Gilead, GlaxoSmithKline, Janssen, Lilly, Nordic Pharma, Pfizer, Roche, Sanofi, and UCB
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. This information is brought to you by Touch Medical Media and is not […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. This information is brought to you by Touch Medical Media and is not sponsored by, nor […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!